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Abstract
Background: Cluster headache (CH) is a rare, excruciating and highly disabling primary headache disorder. Using
non cluster headache specific measures, previous studies have shown that CH has a significant negative impact on
patients’ quality of life (QoL), but a CH-specific QoL scale is currently unavailable. Thus, the objective of this study
was to develop and validate a CH-specific QoL scale.
Methods: Based on a literature review, semi-structured patient interviews and expert panel consultation, we
produced a 54-item questionnaire, which was pre-tested in a sample of CH patients and subsequently reduced to
47 items. The revised scale was then administered to CH sufferers attending a tertiary headache clinic and those
registered with a patient group. A total of 406 completed questionnaires were received. To assess test-retest
reliability, a subsample (N = 56) completed the scale on a second occasion, two weeks after the first. Standard
statistical methods were used to analyse the data for validity and reliability.
Results: Item reduction and exploratory factor analysis led to 28-items, grouped into four subscales labelled
“restriction of activities of daily living”, “impact on mood and interpersonal relationships”, “pain and anxiety”, and
“lack of vitality”. The final CH-specific QoL scale, the CHQ, demonstrated satisfactory internal consistency (Cronbach’s
alpha > 0.9) and test-retest reliability (intraclass correlation coefficient > 0.8), with good internal construct validity
between subscales (range 0.52–0.75) and convergent validity with other QoL measures.
Conclusions: We have developed and validated the first patient-reported outcome measure of QoL specifically for
CH sufferers, which may be used to monitor QoL in clinical care and research.
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Background
Quality of life (QoL) scales have increasingly emerged as
an important clinical outcome measure for assessing the
impact of a disorder and its treatment on patients’ well-
being [3, 18]. Within the headache field, much of the
interest in this area has been focused on migraine, due
to its high prevalence. A number of disease-specific QoL
instruments have been developed for migraine [11, 14,
17, 23]. Similar measures for other primary headache
types, such as cluster headache, are not yet available.
Cluster headache (CH) is a rare, excruciating and
highly disabling headache that is strictly lateralised, typ-
ically associated with prominent cranial autonomic fea-
tures or a sense of restlessness or agitation [10, 12]. In
CH, assessment of QoL is currently limited to use of
generic scales, such as the SF-36, and headache disability
instruments, which have shown significantly diminished
scores compared to headache-free controls [2, 5, 7, 16,
21]. Moreover, a study found significant differences be-
tween CH patients in the ictal versus the interictal
period, but no significant differences between CH pa-
tients and migraineurs [7]. The authors postulated that
since the study used a migraine-specific measure, it
might not have been able to truly capture the essential
aspects of CH [7]. In light of this and the differences be-
tween the two headache entities, we aim to develop a
CH-specific QoL tool, which may better reflect the true
nature of the daily life impact of this highly disabling
disorder. We report the development and validation of a
disease-specific QoL instrument for CH.
Methods
Ethical approval for this study was obtained from The
North West London Research Ethics Committee (Date
of ethics approval: 26 July 2010, Ethics ID number: 10/
H0722/43). Informed written consent was obtained from
all participants prior to enrolment in the study. Data
was collated in an electronic database and all statistical
analyses were performed using SPSS-PASW software
version 18. A three-step approach was employed in the
development and validation of the scale: first item gener-
ation; second item reduction and scale development;
and, finally scale validation and reliability testing.
Item generation
A comprehensive review of the literature was conducted
and existing headache-specific QoL scales were studied
to generate an overview of the areas of life impacted by
CH. This was followed by an in-depth semi-structured
interview of 24 episodic and chronic CH patients in
2010 (M:F 2.6:1, mean age 46.3 years), diagnosed accord-
ing to the diagnostic criteria of the International Classifi-
cation of Headache Disorders (ICHD-II) [12], who are
registered with the headache clinic at The National
Hospital for Neurology and Neurosurgery, London and
were living in and around the Greater London area. The
topics covered during the interview included pain char-
acteristics, aspects of the patient’s life that were affected
by their headaches, their support system, and their out-
look on life. These processes allowed generation of a
preliminary questionnaire, which was then discussed
with a panel of experts with an interest in headache.
Any ambiguous or similar items were eliminated or
grouped together, before a final set of items were agreed
upon. A 54-item questionnaire was subsequently drafted,
each with a range of five possible answers on a Likert
scale: never, occasionally, sometimes, often and always,
addressing areas of life impacted by CH within the past
month or during their last cluster bout. A visual
analogue scale (VAS) was added to the end of the
questionnaire to rate overall satisfaction with life (0 = ex-
tremely dissatisfied, 100 = extremely satisfied). Subse-
quently, a pilot study was conducted with 24 CH
patients to assess the face validity and clarity, and the
questionnaire was then adjusted accordingly and re-
duced to 47-items.
Item reduction and scale development
There were two sources of CH participants for this
study: (i) Patients with a diagnosis of CH attending the
headache clinic at The National Hospital for Neurology
and Neurosurgery, London and (ii) an invitation letter to
participate in the survey was posted out to CH partici-
pants via OUCH UK (The Organisation for the Under-
standing of Cluster Headache, United Kingdom). Those
who responded to the invitation letter were contacted
via telephone and had their headaches phenotyped via a
telephone interview. Inclusion criteria for the study were
those who had a clinical diagnosis of CH, whilst the
exclusion criteria were those who had other major
neurological, psychiatric or physical illness. A booklet of
questionnaires, which included the 47-item CH-QoL
questionnaire was then given or posted out to all partici-
pants who satisfied the ICHD-II diagnostic criteria for
CH (n = 521) from 2011 to 2013. Details on demograph-
ics, headache history and characteristics were collected
from the questionnaires. A number of other frequently
utilised generic or headache specific QoL instruments
were also included in the booklet to allow assessment of
convergent validity of this new scale, including the SF-36
Health Survey Questionnaire, the EuroQoL (EQ-5D)
Questionnaire and the Migraine-Specific Quality of Life
Questionnaire Version 2.1 (MSQ v2.1).
The SF-36 Health Survey Questionnaire is a generic
QoL measure with excellent reliability and validity [24].
It contains 36 self-administered items, measuring func-
tions in eight domains; physical functioning (PF), role-
physical (RP), bodily pain (BP), general health (GH),
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vitality (VT), social role functioning (SF), emotional role
functioning (EF) and mental health (MH). The subscales
are scored on a scale of 0 to 100, with higher scores in-
dicating better QoL in the domain being measured [24].
The EuroQoL (EQ-5D) Questionnaire is a generic
measure of current health status. It consists of five do-
mains: mobility, self-care, usual activities, pain/discom-
fort and anxiety/depression. In addition, there is a visual
analogue scale, with 0 being the worst imaginable and
100 being the best imaginable current health state [19].
The Migraine-Specific Quality of Life Questionnaire
Version 2.1 (MSQ v2.1) is a 14-item measure specifically
developed to assess the QoL in patients with migraine.
The items are divided across three domains; role re-
strictive, role preventive and emotional functioning. This
questionnaire has been shown to have good internal
consistency and construct validity [17]. The total pos-
sible score ranges from 14 to 84, with higher scores indi-
cating poorer QoL.
A total of 406 completed questionnaires were received,
giving a response rate of 77.9 %. From this total, 36.5 %
were recruited from the headache clinic and 63.5 % were
recruited from OUCH UK. About fifty-nine percent of
the responders had episodic CH and 41.1 % had chronic
CH. The mean age of the study sample was 52.4 years
(range 20.5–84.4). There were 68.2 % males and 31.8 %
females, with a mean age of onset of CH of 33.0 years
(range 8.0–69.0).
Intercorrelation between variables was performed on
the data generated from the survey. Items that showed
low intercorrelations (r < 0.1) were excluded as this dem-
onstrated that they were poorly correlated with the
underlying scale. On the other hand, any items that
showed high intercorrelations (r > 0.7) [6] were exam-
ined and the least clinically sensible item was excluded,
as theoretically items that correlated too highly are
measuring the same underlying dimension [8].
Scale validation and reliability testing
Construct validity was assessed with an exploratory fac-
tor analysis to determine the key components of the 47-
item questionnaire. Oblique rotation was used for the
analysis, as we had reason to believe that the resulting
factors would correlate with each other. An eigenvalue
cut off point >1 was used to extract underlying factors.
Concurrent validity was assessed by measuring the Pear-
son’s correlation of the underlying subscales of the CH-
specific HRQoL questionnaire with the subscales of SF-
36 and MSQ v2.1. Meanwhile, Spearman’s correlation
test was employed to assess validity of the questionnaire
and the EQ-5D, due to the ordinal nature of the latter.
A second copy of the 47-item questionnaire was sent
out to 75 respondents (approximately 15 % of the main
validation sample size) two weeks after the first
completion of it to allow assessment of the test-retest re-
liability of the new scale. Fifty-six completed question-
naires were received (71.7 % response rate) for the
assessment of test-retest reliability. The mean age of this
subsample was 55.7 years (range 34.7–79.1). There were
66.1 % males and 33.9 % females, with a mean age of on-
set of CH of 36.4 years (range 12.0–66.0).
Results
Participants
There were no significant differences in the sociodemo-
graphic and headache characteristics of the participants
based on the source of their recruitment, as shown in
Table 1. Moreover, no significant differences were found
in the CH-specific HRQoL scores between males and
females.
Construct validity
The exploratory factor analysis produced five factors,
consisting of 37 items. One factor with an eigenvalue of
1.11 (explaining 3.1 % of the variance) was removed as it
only had one item loading onto it and therefore was
considered insufficient to produce a meaningful subscale
[22]. The remaining factors and items were then exam-
ined to determine if there was any scope for further re-
duction of the number of items to produce a more
meaningful and user-friendly scale. Eight items were
omitted as they failed to gain significant loading (>0.4)
on any of the factors created. This resulted in a 28-item
questionnaire (CHQ), which explained 56.1 % of the
variance (Table 2). The Cronbach’s alpha was calculated
and compared for the factors prior to, and after removal
of these items, to ensure that it did not compromise the
internal consistency of the scale [4]. Expert opinion was
also sought throughout this process to ensure there was
no removal of clinically relevant items.
Based on the results of the factor analysis, nine items
were grouped onto a factor addressing various ‘Restric-
tions of activities of daily living’ (ADL), such as avoiding
leaving the house, making plans and inability to
complete duties at work. Twelve items described ‘Impact
on mood and interpersonal relationships’, such as feelings
of being dismissed by others and worthlessness, includ-
ing any suicidal tendencies. Two items loaded on a ‘Pain
and anxiety’ factor, which addressed the pain of the clus-
ter headache and any associated anxiety such as dread-
ing that the headache not going away. Finally, a ‘Lack of
vitality’ (five items) factor addresses problems related to
energy and cognition, for example difficulties in thinking
clearly and concentration. There was good intercorrel-
ation between the subscales (range 0.52–0.75) derived
from the factor analysis, supporting internal construct
validity. There was also a moderate correlation between
the total score and the VAS (r = −0.57, p < 0.01). This
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negative correlation was expected as their scores ran in
opposite direction (higher VAS indicates better HRQoL
whereas higher total score indicates poorer HRQoL).
Internal consistency and test-retest reliability
The scale had a Cronbach’s coefficient alpha (α) of 0.95,
which was well above the recommended criteria of 0.70.
The internal consistency and corrected item to total cor-
relations of the items to their resulting subscale is shown
in Table 3. Test-retest reliability testing of the scales was
performed on the data collected from respondents who
completed the questionnaire on two occasions, which
showed significant correlation between the two assess-
ment occasions (intra class correlation coefficient was
0.87). Cronbach’s alpha was also satisfactory for the
scales on both occasions (Table 4).
Convergent validity
The scale was assessed for convergent validity by meas-
uring correlation of the subscales with the relevant sub-
scales of the EQ-5D, SF-36 and MSQ (Table 5). With
regards to the EQ-5D, the CHQ subscales showed low
to moderate correlations with all of the EQ-5D domains,
except for the pain and anxiety subscale of CHQ
and the mobility and self-care domains (EQ-5D).
The highest correlation observed was between the
‘Impact on mood and interpersonal relationships’
subscale of the CHQ and anxiety/depression item of
the EQ-5D (rs = 0.54, p < 0.01).
Similarly, there were low to moderate correlations with
the SF-36 and MSQ subscales. The ‘Restrictions of ADL’
factor of CHQ correlated significantly with the social
role functioning (SF) (r = −0.47, p < 0.01) and emotional
role functioning (RE) subscales (r = −0.41, p < 0.01). The
‘Impact on mood and interpersonal relationships’
subscale of the CHQ correlated highly with mental
health (MH) (r = −0.67, p < 0.01) and moderately with
SF (r = −0.52, p < 0.01), RE (r = −0.50, p < 0.01) and vital-
ity (VT) (r = −0.49, p < 0.01) subscales. The ‘Lack of vi-
tality’ subscale of the CHQ correlated moderately with
VT (r = −0.43, p < 0.01) and RE (r = −0.39, p < 0.01). All
the correlations were negative as the CHQ and SF-36
were scored in different directions. In relation to the
MSQ, the CHQ subscales correlated significantly with
Table 1 Sociodemographic and headache characteristics of the participants based on method of recruitment
Characteristic Total
(n = 406)
NHNN
(n = 148)
OUCH UK
(n = 258)
p values*
Age, mean ± SD 52.4 ± 12.3 51.1 ± 12.1 53.2 ± 12.4 0.109
Gender (male: female) 2.1: 1 2.2: 1 2.1: 1 0.820
Marital status, n (%) 0.079
Single 60 (14.9 %) 25 (16.9 %) 35 (13.7 %)
Married/cohabiting 304 (75.2 %) 103 (69.6 %) 201 (78.5 %)
Widowed 12 (3.0 %) 4 (2.7 %) 8 (3.1 %)
Divorced/separated 28 (6.9 %) 16 (10.8 %) 12 (4.7 %)
Years of education, n (%) 0.122
1–11 109 (27.4 %) 45 (31.0 %) 64 (25.3 %)
12–13 73 (18.3 %) 32 (22.1 %) 41 (16.2 %)
14–17 167 (42.0 %) 55 (37.9 %) 112 (44.3 %)
18 + 49 (12.3 %) 13 (9.0 %) 36 (14.2 %)
Smokers, n (%) 186 (45.8 %) 70 (47.2 %) 116 (45.0 %) 0.649
Duration since onset of CH (years), mean ± SD 19.3 ± 11.5 18.8 ± 10.7 19.6 ± 12.0 0.483
Duration of CH (minutes), mean ± SD 46.5 ± 58.8 48.6 ± 52.9 45.2 ± 62.1 0.601
Frequency of CH attacks (number/day), mean ± SD 3.5 ± 2.4 3.5 ± 2.1 3.5 ± 2.5 0.892
Severity of CH attacks, n (%) 0.057
Mild 1 (0.2 %) 1 (0.7 %) 0 (0.0 %)
Moderate 15 (3.7 %) 9 (6.1 %) 6 (2.3 %)
Severe 29 (7.1 %) 15 (10.1 %) 14 (5.4 %)
Very severe 61 (15.0 %) 20 (13.5 %) 41 (15.9 %)
Excruciating 300 (73.9 %) 103 (69.6 %) 197 (76.4 %)
NHNN The National Hospital for Neurology and Neurosurgery, OUCH UK The Organisation for the Understanding of Cluster Headache, United Kingdom, CH cluster
headache, SD standard deviation
*Based on two-sample t-tests for continuous variables and Chi-square tests for categorical variables
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the all domains. Furthermore, the ‘Impact on mood and
interpersonal relationships’ subscale of the CHQ and
emotional functioning domain of the MSQ were well
correlated (r = 0.65, p < 0.01), supporting good conver-
gent validity.
The mean scores of the CHQ in episodic CH patients
were then compared to those of chronic CH patients.
Patients with chronic CH had significantly greater im-
pairment in their QoL compared to their episodic coun-
terparts (61.6 ± 18.9 vs 56.2 ± 19.0, p = 0.010), further
supporting good validity and sensitivity of the question-
naire to detect impairment specifically related to CH.
Discussion
Several studies have demonstrated that QoL is signifi-
cantly impaired in patients with CH, more so in chronic
sufferers, with considerable impact on daily living e.g.,
efficiency and ability to work and social functioning,
with almost 20 % of patients losing their jobs secondary
to the disorder [5–7, 13, 15, 20, 21]. However, these
studies have all used either generic QoL scales such as
the SF-36, or migraine-specific scales that may not
necessarily be able to capture the true effects of CH, and
may therefore be underestimating the actual impact of the
disorder on QoL. Indeed, some instruments specifically
Table 2 Results of the principal component factor analysis of the CHQ scale
Items Factor 1
Restriction
of ADL
Factor 2
Impact on
mood and
interpersonal
relationships
Factor 3
Pain and
anxiety
Factor 4
Lack of
vitality
Avoided leaving the house 0.76
Avoided making plans due to unpredictability of CH e.g., holidays 0.72
Felt unable to complete duties at work 0.66
Had difficulty in getting involved in leisure activities e.g., cinema, theatre, etc.? 0.63
Avoided crowded and noisy places e.g., public transport, pubs, etc. 0.57
Felt that the severity of cluster headache affected your daily activities 0.56
Been less involved in family affairs e.g., interaction with children, planning holidays 0.54
Been unable to socialise/spend time with friends and family 0.46
Been unable to achieve your daily goals and carry out routines and chores 0.42
Felt less respected by others 0.89
Had problems with close personal relationship 0.73
Felt you were a burden on family and friends 0.71
Felt self-conscious and uncomfortable about your appearance after a cluster
headache attack (e.g., swelling/redness of eyes and facial sweating, etc.)
0.68
Felt that others are dismissive of your cluster headaches 0.61
Felt aggressive 0.53
Felt bad about yourself, lost self-confidence or felt worthless 0.53
Felt like harming yourself or suicidal 0.53
Been irritable, impatient or less tolerant 0.53
Been forgetful e.g., missed appointments 0.49
Been unable to take care of your appearance (e.g., take a bath, put make-up on, change
clothes etc.)
0.49
Felt isolated, lonely or vulnerable 0.45
Found your pain is unbearable if untreated 0.67
Dreaded that the headache would not go away 0.48
Felt lacking in energy and constantly tired −0.88
Felt sleepy, worn out or less able to concentrate due to nocturnal attacks of CH −0.72
Had problems concentrating e.g., reading paper, watching TV, etc. −0.62
Been unable to think clearly −0.60
Felt tense or anxious −0.48
% of variance explained 43.11 5.59 4.06 3.38
CHQ cluster headache specific quality of life, ADL activities of daily living
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ask about suffering in the past four weeks, thus ECH suf-
ferers out of a bout would rate low scores on these scales,
even though they may be severely impaired during a bout
[9]. Hence, these measures may not provide a true reflec-
tion of the actual impairment. Moreover, issues that are
specific to CH are not addressed through the use of these
scales, for example suicidal tendencies, which is prevalent
among CH sufferers. Circadian periodicity is another dis-
tinct feature in this disorder, with sufferers usually being
woken up around the same time every night, at the onset
Table 3 Item to total correlations and Cronbach’s alpha for the CHQ scale
Scale/Items Corrected item
to total correlation
Cronbach’s alpha
Restriction of ADL 0.91
Avoided leaving the house 0.67
Avoided making plans due to unpredictability of CH e.g., holidays 0.66
Felt unable to complete duties at work 0.70
Had difficulty in getting involved in leisure activities e.g., cinema, theatre, etc.? 0.78
Avoided crowded and noisy places e.g., public transport, pubs, etc. 0.63
Felt that the severity of cluster headache affected your daily activities 0.68
Been less involved in family affairs eg interaction with children,planning holidays 0.67
Been unable to socialise/spend time with friends and family 0.73
Been unable to achieve your daily goals and carry out routines and chores 0.69
Impact on mood and interpersonal relationships 0.90
Felt less respected by others 0.72
Had problems with close personal relationship 0.71
Felt you were a burden on family and friends 0.73
Felt self-conscious and uncomfortable about your appearance after a cluster headache attack
(eg swelling/redness of eyes and facial sweating, etc.)
0.65
Felt that others are dismissive of your cluster headaches 0.50
Felt aggressive 0.59
Felt bad about yourself, lost self-confidence or felt worthless 0.63
Felt like harming yourself or suicidal 0.59
Been irritable, impatient or less tolerant 0.63
Been forgetful e.g., missed appointments 0.58
Been unable to take care of your appearance (eg take a bath, put make-up on, change clothes etc.) 0.55
Felt isolated, lonely or vulnerable 0.71
Pain and anxiety 0.52
Found your pain is unbearable if untreated 0.37
Dreaded that the headache would not go away 0.37
Lack of vitality 0.85
Felt lacking in energy and constantly tired 0.69
Felt sleepy, worn out or less able to concentrate due to nocturnal attacks of CH 0.61
Had problems concentrating e.g., reading paper, watching TV, etc. 0.64
Been unable to think clearly 0.70
Felt tense or anxious 0.66
Table 4 Cronbach’s alpha and test-retest reliability at the first
and second assessment occasions
Scale Cronbach’s
alpha time 1
Cronbach’s
alpha time 2
Test-retest
reliability
Restriction of ADL 0.91 0.93 0.84 p < 0.01
Impact on mood and
interpersonal relationships
0.90 0.87 0.83 p < 0.01
Pain and anxiety 0.52 0.63 0.71 p < 0.01
Lack of vitality 0.85 0.80 0.80 p < 0.01
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of rapid eye movement (REM) sleep, which can have a
major impact on patients with CH. We have therefore
developed a questionnaire based on both patient and ex-
pert views of the disorder. To our knowledge, this is the
first scale developed to measure QoL specifically in CH
sufferers.
In the current study, we developed and validated a
CH-specific QoL scale, the CHQ. Items for the scale
were generated from an in-depth literature review and
semi-structured patient interviews, allowing CH suf-
ferers to express their views about the various aspects of
their lives that they felt were affected by the disorder
and should be highlighted in such a disease specific QoL
scale. This was followed by a review by a panel of ex-
perts with an interest in headaches to include items that
were considered clinically relevant. These steps allowed
us to develop a scale that is based on both patient and
clinician input, thus ensuring good content and face
validity. Furthermore, following administration to a large
sample of participants with CH, the scale has also been
shown to have good construct validity, internal
consistency and test-retest reliability. In terms of conver-
gent validity, the subscale scores showed good correl-
ation with those of other widely used QoL scales that
have already been shown to have good validity and reli-
ability, specifically the EQ-5D, SF-36 and MSQ. More-
over, the scale has been able to detect significantly
greater impairment in QoL in chronic CH patients,
compared to episodic CH patients, thus showing good
sensitivity.
A limitation of this study was that about a third of our
study population comprised patients attending a tertiary
referral centre; hence medically intractable cases may be
over-represented in our sample. Of the 148 patients re-
cruited from the headache clinic, 64.2 % had chronic
CH, which is significantly greater than is expected in the
general population [1]. Thus our sample may not be to-
tally representative of the CH population in the commu-
nity. However, this bias enabled us to collect data from a
fair proportion of chronic CH sufferers (42.9 %), who
due to the recurring nature of their headaches are likely
to be more disabled by this disorder, giving us a better
picture of the extent of the impact on patients QoL.
Since the development of the questionnaire involved
both CH patients and a panel of experts, we strongly be-
lieve that the items included in our questionnaire were
equally important for both ECH and CCH sufferers. Fur-
thermore, despite the different methods of recruitment,
it could be argued that those recruited via OUCH UK
were also significantly affected by their CH to warrant
them to seek help, as shown by the lack of significant
differences in their headache characteristics from those
recruited through the hospital, hence, supporting our
decision to group them together.
Table 5 Correlation coefficients (p values) between the CHQ subscales and the EQ-5D and SF-36 generic and MSQ v2.1 migraine-specific
quality of life measures
Restriction of ADL Impacts on mood and interpersonal relationships Pain and anxiety Lack of vitality
EQ-5D
Mobility 0.28a 0.27a 0.07c 0.21a
Self-care 0.31a 0.39a 0.10b 0.27a
Usual activities 0.35a 0.43a 0.14a 0.29a
Pain/discomfort 0.19a 0.30a 0.11b 0.14a
Anxiety/depression 0.39a 0.54a 0.28a 0.38a
SF-36
Physical functioning (PF) −0.27a −0.37a −0.11b −0.24a
Role physical (RP) −0.23a −0.32a −0.05c −0.19a
Bodily pain (BP) −0.23a −0.31a −0.12b −0.22a
General health (GH) −0.34a −0.46a −0.15a −0.32a
Vitality (VT) −0.37a −0.49a −0.22a −0.43a
Social functioning (SF) −0.47a −0.52a −0.21a −0.37a
Role emotional (RE) −0.41a −0.50a −0.21a −0.39a
Mental health (MH) −0.51a −0.67a −0.37a −0.50a
MSQ v2.1
Role restrictive (RR) 0.51a 0.53a 0.29a 0.45a
Role preventive (RP) 0.56a 0.52a 0.28a 0.42a
Emotional functioning (EF) 0.49a 0.65a 0.41a 0.47a
ap < .01: bp < .05: cnon-significant
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Conclusions
We have developed the first objective measure of QoL
specifically for CH sufferers, which we have intended to
be brief and user-friendly as it takes about 10 min to
complete the questionnaire. We hope that it can be used
in the clinical setting to monitor QoL as part of patient
care, as well as in clinical trials as a patient-reported out-
come measure. The next stage in the validation of the
CHQ will be an assessment of its sensitivity to capture
change in QoL over time (e.g., in the active and remis-
sion phases in episodic CH) and following medical and
surgical treatments of CH. Further studies will also need
to be performed in other community populations as the
development and validation of this scale was based solely
on a sample of CH population in the United Kingdom.
Future studies could also examine age or gender related
differences in QoL in CH with the CHQ. Once the CHQ
has been fully validated and its sensitivity to change
established, it could serve as an appropriate measure for
identifying the demographic (e.g., age, gender, socioeco-
nomic status), clinical (e.g., severity of pain, frequency of
episodes, distribution of pain), psychological (mood,
anxiety), social (e.g., social support) and behavioural
(e.g., ways of coping, avoidance) factors that predict QoL
in CH. Such information would be valuable in steering
clinical management to focus on aspects of the disease
that would help enhance QoL of CH sufferers.
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